A vial label can claim 99% purity, but peptide purity testing is only meaningful when the claim is tied to a specific lot, a defined analytical method, and documentation from a credible independent laboratory. Without those elements, a purity percentage is marketing copy, not usable quality evidence.
For research-use-only peptide buyers, the practical question is not whether a supplier displays a Certificate of Analysis. It is whether that COA establishes what is actually in the vial, how much is present, and whether the report belongs to the product being offered. Those are separate questions, and a single generic report often cannot answer all three.
What Peptide Purity Testing Actually Measures
Purity is commonly reported as the percentage of the tested material attributed to the target peptide. High-performance liquid chromatography, usually called HPLC, is the method most often used to produce that figure. The method separates components in a sample into peaks. A reported purity of 99%, for example, generally means the target peak represents approximately 99% of the measured chromatographic signal under that method's conditions.
That result is useful, but it has limits. HPLC can show whether a sample contains detectable related impurities or degradation products. It does not, by itself, conclusively establish the peptide's molecular identity. It also does not automatically prove the stated mass of peptide in a vial.
A credible testing package separates three core quality questions:
Identity: Is the material the peptide named on the label? Mass spectrometry, such as LC-MS or MALDI-TOF, is commonly used to confirm expected molecular mass.
Purity: What proportion of the tested sample corresponds to the target compound under the stated method? HPLC or UPLC is commonly used here.
Net content: Does the vial contain the stated amount of material? This requires a content or assay result, not merely a purity percentage.
These distinctions matter with every compound, from BPC-157 and TB-500 to Semaglutide, Tirzepatide, and GHK-Cu. A product may show a clean chromatogram while still having an identity problem, an inaccurate fill amount, or a COA that cannot be connected to the lot in hand.
Why a High Purity Percentage Is Not Enough
The most common mistake in COA review is treating a high HPLC percentage as a complete quality verdict. It is not. A 99% result may be encouraging, but its value depends on the report's scope and traceability.
First, ask what the percentage refers to. Chromatographic area purity is not always the same as absolute peptide content. Different compounds can produce different detector responses, and some analytical methods are better suited to estimating relative composition than confirming precise mass. If a supplier sells a vial labeled with a specific milligram amount, researchers should look for evidence that addresses fill or net content separately.
Second, consider whether the testing method can distinguish the claimed peptide from closely related materials. Peptides can degrade, aggregate, retain synthesis-related impurities, or contain sequence variants. HPLC separation provides valuable information, but mass-based identity confirmation gives the purity result context.
Third, check whether the reported result is current and lot-specific. A COA for a prior batch, a stock image of a report, or an undated certificate does not verify the inventory currently being sold. Quality evidence loses practical value when it cannot be matched to the exact product lot.
What an Independent COA Should Show
A usable COA should allow a buyer to verify the connection between the report, the laboratory, the tested material, and the listed result. It should not require blind trust in a supplier's screenshot or summary graphic.
At minimum, review the product name, lot or batch number, test date, laboratory name, analytical method, and numerical results. The lot number on the COA should match the vial, packaging, or product-specific batch information provided by the supplier. If the vendor cannot explain how to make that match, treat the document as incomplete evidence.
The report should also identify the sample in a way that makes substitution difficult. Generic labels such as “peptide sample” or “customer sample” are weaker than a report naming the compound and associated lot. A laboratory report number, analyst approval, and date of issuance add traceability, although formatting will vary among labs.
Method transparency matters. A COA that says only “purity: 99%” gives less information than one stating HPLC or UPLC conditions, detection approach, chromatogram reference, and acceptance criteria. Buyers do not need to become analytical chemists to recognize the difference between a real test record and a promotional certificate. The first shows how a conclusion was reached. The second asks the reader to accept a conclusion without evidence.
The Testing Tiers That Change a Vendor Comparison
Identity, purity, and net content are the baseline. They establish the most basic question: whether the product appears to be what the label claims. For many research applications, additional testing categories materially improve the quality picture.
Sterility testing evaluates whether viable microorganisms are detected under specified test conditions. Endotoxin testing evaluates bacterial endotoxin contamination, commonly reported in endotoxin units. Heavy metals testing screens for elemental contaminants that may arise from raw materials, equipment, or processing. Conformity testing can add further confirmation that a product aligns with stated specifications, though the exact scope should be read rather than assumed.
These tests are not interchangeable. A sterile result does not prove identity or purity. A clean HPLC chromatogram does not establish sterility. An endotoxin result does not confirm net peptide content. Vendors that present one test as proof of every quality attribute are collapsing distinct standards into a marketing claim.
There is also a trade-off. Expanded testing is more informative, but it can be more expensive and may not be performed on every lot. The relevant standard depends on the research context and the claims a vendor makes. What does not depend on context is the need for documentation to be specific, current, and independently generated.
How to Review a COA Before Relying on It
Start with traceability, then read the results. Confirm that the batch number is visible and that the COA dates make sense for current inventory. Look for an independent laboratory rather than a vendor-created document that uses laboratory-style language without identifying who performed the work.
Next, verify that identity and purity are both addressed. For identity, look for LC-MS, mass spectrometry, or another method capable of confirming expected molecular mass. For purity, look for HPLC or UPLC results and a numerical value. If net content is a stated selling point, look for a separate assay, content, or fill verification result.
Then inspect what is missing. A supplier may have a legitimate reason for not publishing every raw data file, but it should be able to state what was tested, when, by whom, and for which lot. A refusal to provide current lot-specific documentation is not a minor customer-service issue. It is a qualification failure.
Finally, watch for signs that a report may not be reliable: altered formatting, cropped lab identifiers, mismatched product names, vague sample descriptions, repeated reports across different batches, or certificates dated far earlier than the product release. None of these alone proves misconduct. Together, they justify caution and a request for clarification.
Independent Testing Is the Baseline, Not a Premium Feature
Supplier claims deserve evidence because research-use-only labeling does not substitute for quality control. “Research grade,” “pharmaceutical grade,” and similar phrases are not analytical methods. Nor does a discount, a popular social media presence, or a polished website establish product contents.
RUO Codes treats current, independent-lab COAs confirming identity, purity, and net content as the baseline for vendor inclusion. Higher testing tiers for sterility, endotoxin, heavy metals, and conformity testing provide additional context when comparing suppliers. The point is not to imply that every test answers every question. It is to make the available evidence visible so buyers can distinguish documented quality controls from unverified claims.
A COA also should not be treated as a safety guarantee or as authorization for human use. Research-use-only materials are not approved medicines, and analytical documentation cannot change their regulatory status. It can only help establish whether a supplier has produced evidence for the product it represents.
The most useful habit is simple: ask for the lot-specific record before relying on the product claim, and read beyond the purity percentage. When a vendor can document identity, purity, content, and relevant contamination controls, it gives researchers something concrete to evaluate. When it cannot, the missing evidence is itself a decision-making signal.